Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more
Wuhan Hiteck Biological Pharma Co Ltd (300683) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.008x
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has a cash flow conversion efficiency ratio of -0.008x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.49 Million) by net assets (CN¥2.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wuhan Hiteck Biological Pharma Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Union Holdings Ltd
SHE:000036
|
-0.005x |
|
Zepp Health Corp
NYSE:ZEPP
|
0.416x |
|
Memsensing Microsystems Suzhou China Co Ltd
SHG:688286
|
0.002x |
|
Genusplus Group Ltd
AU:GNP
|
0.609x |
|
CYTEK BIOSCIENCES DL-001
F:8EQ
|
N/A |
|
Kinepolis Group NV
BR:KIN
|
0.345x |
|
Beijing Water Business Doctor
SHE:300055
|
0.001x |
|
Hengxin Mobile Business
SHE:300081
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.41 Billion | CN¥22.69 Million | 0.009x | +341.74% |
| 2023-12-31 | CN¥2.50 Billion | CN¥5.31 Million | 0.002x | -90.62% |
| 2022-12-31 | CN¥2.34 Billion | CN¥53.03 Million | 0.023x | +340.20% |
| 2021-12-31 | CN¥2.34 Billion | CN¥12.09 Million | 0.005x | +145.17% |
| 2020-12-31 | CN¥1.72 Billion | CN¥-19.70 Million | -0.011x | -131.90% |
| 2019-12-31 | CN¥1.76 Billion | CN¥63.03 Million | 0.036x | -16.64% |
| 2018-12-31 | CN¥1.71 Billion | CN¥73.42 Million | 0.043x | -15.06% |
| 2017-12-31 | CN¥1.64 Billion | CN¥83.08 Million | 0.051x | -75.28% |
| 2016-12-31 | CN¥703.35 Million | CN¥143.86 Million | 0.205x | -23.66% |
| 2015-12-31 | CN¥596.76 Million | CN¥159.89 Million | 0.268x | +6.18% |
| 2014-12-31 | CN¥536.59 Million | CN¥135.40 Million | 0.252x | -16.35% |
| 2013-12-31 | CN¥254.64 Million | CN¥76.82 Million | 0.302x | -- |